Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.